Stay updated on Genetic Predictors of Benefit to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Genetic Predictors of Benefit to Pembrolizumab Clinical Trial page.

Latest updates to the Genetic Predictors of Benefit to Pembrolizumab Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to reflect a new version (v2.15.0) and includes the addition of collaborators such as Merck Sharp & Dohme LLC, Massachusetts General Hospital, and the National Cancer Institute (NCI). However, significant details regarding the study's objectives and criteria for patient enrollment have been removed.SummaryDifference37%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.9%
Stay in the know with updates to Genetic Predictors of Benefit to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Genetic Predictors of Benefit to Pembrolizumab Clinical Trial page.